News

Deal Announcements

MyoKardia Receives Series B Venture Capital

Friday, May 1, 2015 5:47:00 AM PDT | VentureDeal
   South San Francisco, California  --  Biotechnology company MyoKardia has secured $46 million in its second round of institutional venture capital financing.

MyoKardia is developing novel therapeutic treatments for hypertrophic and dilated cardiomyopathy.

The company says that these two conditions together afflict 1 million people in United States alone.

Investors in the round included Sanofi, Casdin Capital, Cormorant Asset Management, Perceptive Advisors and others.

MyoKardia will use the proceeds to advance its portfolio of possible therapies for these two conditions, notably its lead drug candidate MYK-461.

Email Page  Email Page | Print Page Print Page

Free Trial

Want unlimited access to the complete database with thousands of technology companies, VCs and transactions for only $25 per month?

Start your Free 14 Day Trial now – no obligation or credit card required.

Free 14 day trial. No Obligation. Click to Register.
Venturedeal Twitter Venturedeal Facebook Venturedeal Linkedin


PCI - Level1